Nuvion Pharmaceutical Group

Hong Kong private limited company · research peptide manufacture & release

CERTIFICATE OF ANALYSIS

Analytical Test Report

NV-COA-2026-09252

TASK NUMBER	PRODUCT SKU	BATCH / LOT	DISPOSITION
NV-9252	IG1	NV-IG1-2026-05	PASS — Released

SAMPLE & CLIENT

Client (ordered by)	**Nuvion Canada**	**Manufacturer**	Nuvion Pharmaceutical Group (GMP manufacture)
Sample	**IGF-1 LR3 - 1mg**	**Batch**	NV-IG1-2026-05
Product SKU	IG1	**Form**	Lyophilized peptide powder
Dosage / strength	1mg	**Expiry (sealed)**	14 MAY 2028

TIMELINE

Testing ordered	07 APR 2026	**Sample received**	27 APR 2026
Analysis conducted	22 APR 2026	**Report issued**	18 OCT 2026

SAMPLE DESCRIPTION

Sealed research vial(s) of lyophilized peptide powder, labeled IGF-1 LR3 - 1mg. Visual inspection: white to off-white cake/ powder. Pictures not included.

TESTS REQUESTED

- Identity confirmation by mass spectrometry (MS)
- Purity determination by reverse-phase HPLC (UV 220 nm)
- Net peptide content / assayed quantity
- Assessment of a peptide vial for research-use release

RESULTS

ANALYTICAL SUMMARY — Identity ESI-MS · Purity HPLC

IGF-1 LR3 — **1 mg**

HPLC PURITY	IDENTITY	APPEARANCE
99.620%	Confirmed — IGF-1 LR3	White lyophilized powder

COMMENTS

Sample meets Nuvion release specification (≥99.0% HPLC purity; identity confirmed by MS). Lot released for research use only.

Quality Assurance

Authorized Signatory — Quality Control

Nuvion Pharmaceutical Group Quality Control · Analysis conducted › 22 APR 2026

This certificate relates only to the sample tested and to the batch identified herein.

NV-IG1-8BAC845B

Scan QR or open buynuvion.com/verify

RUO. For laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, treatment, or consumption. Not a drug, food, or cosmetic. Handle in accordance with institutional laboratory safety protocols.

Nuvion Pharmaceutical Group

Analytical detail

METHOD & DATA

IGF-1 LR3 - 1mg · SKU IG1

NV-COA-2026-09252

COMPOUND IDENTIFIERS

Compound	IGF-1 LR3	**CAS**	137525-51-0
Molecular formula	C62H98N16022	**MW (Da)**	1419.53
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val		


IDENTITY — MASS SPECTROMETRY

Method	ESI-MS
Theoretical mass	1419.53 Da
Observed mass	1419.48 Da
Mass error	-35.2 ppm
Conclusion	**Confirmed — IGF-1 LR3**

HPLC METHOD PARAMETERS

METHOD RP-HPLC	COLUMN C18, 4.6 × 250 mm, 5 µm
MOBILE PHASE A 0.1% TFA in water	MOBILE PHASE B 0.1% TFA in acetonitrile
GRADIENT 5–65% B over 30 min	FLOW RATE 1.0 mL/min
DETECTION UV 220 nm	INJECTION / TEMP / RUN 20 µL · 30 °C · 35 min

REPRESENTATIVE CHROMATOGRAM (SCHEMATIC)



PEAK INTEGRATION TABLE

PEAK #	RT (MIN)	AREA	AREA %	ASSIGNMENT
1	8.42	12,480	0.12	Impurity
2	12.18	10,342,110	99.70	BPC-157 (main)
3	14.05	18,650	0.18	Impurity

SPECIFICATION VS RESULT

ATTRIBUTE	SPECIFICATION	RESULT	STATUS
Identity	Matches labeled compound	Confirmed — IGF-1 LR3	**PASS**
Purity (HPLC)	≥ 99.0%	99.620%	**PASS**
Appearance	White to off-white lyophilized powder	White lyophilized powder	**PASS**
Assayed quantity	Consistent with labeled strength	IGF-1 LR3: 1 mg	**PASS**

STORAGE & HANDLING

Lyophilized	Lyophilized: -20 °C, protected from light and moisture
After reconstitution	2–8 °C after reconstitution; use within the stability window for research protocols
Sealed expiry	14 MAY 2028

Document control. Report NV-COA-2026-09252 · Task NV-9252 · SKU IG1 · Batch NV-IG1-2026-05. Verification key NV-IG1-8BAC845B. Issued for Nuvion Canada. For laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, treatment, or consumption. Not a drug, food, or cosmetic. Handle in accordance with institutional laboratory safety protocols.